Novostia Raises Additional CHF 5.6M in Funding

▤ Summary

Novostia, a Lausanne, Switzerland-based medical technology company specializing in the development of a heart valve prosthesis, at clinical stage, closed a CHF 5.6m funding round.The backers were not disclosed.The company intends to use the funds to further accelerate its ongoing development efforts, advancing clinical studies, and preparing for the next financial round.Led by newly named CEO Mrs. Soad El Ghazouani, who is succeeding Mr. Alain Barbal who will join the Board of Directors, Novostia is a medical device company developing an innovative artificial heart valve. The proprietary TRIFLO valve is currently undergoing human clinical trials.Novostia technology is an investigational device not yet approved for sale.

▦ Linked Companies